FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases. The patients will be treated with systemic FOLFOXIRI chemotherapy or FUDR/Oxaliplatin hepatic arterial infusion with CPT-11 systemic chemotherapy.

本试验旨在对比初始不可切除的转移性结直肠癌肝转移患者中，氟尿苷/奥沙利铂（FUDR/Oxaliplatin）肝动脉灌注（hepatic arterial infusion，HAI）联合伊立替康（CPT-11）全身化疗，与FOLFOXIRI全身化疗的客观缓解率。受试者将接受FOLFOXIRI全身化疗，或氟尿苷/奥沙利铂肝动脉灌注联合伊立替康全身化疗。